Alto Neuroscience, Inc.
ANRO
$3.43
$0.020.59%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.78% | 28.60% | 192.04% | 232.72% | 151.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.86% | 8.97% | 44.47% | 94.34% | 101.00% |
| Operating Income | -1.86% | -8.97% | -44.47% | -94.34% | -101.00% |
| Income Before Tax | -10.46% | -13.06% | -35.52% | -83.60% | -85.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.46% | -13.06% | -35.52% | -83.60% | -85.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.46% | -13.06% | -35.52% | -83.60% | -85.04% |
| EBIT | -1.86% | -8.97% | -44.47% | -94.34% | -101.00% |
| EBITDA | -1.56% | -8.51% | -44.40% | -94.34% | -102.24% |
| EPS Basic | -9.81% | 26.43% | 80.90% | 74.52% | 74.45% |
| Normalized Basic EPS | -9.80% | 29.74% | 80.91% | 74.52% | 74.45% |
| EPS Diluted | -9.81% | 26.43% | 80.90% | 74.52% | 74.45% |
| Normalized Diluted EPS | -9.80% | 29.74% | 80.91% | 74.52% | 74.45% |
| Average Basic Shares Outstanding | 0.59% | 53.69% | 609.62% | 620.44% | 624.25% |
| Average Diluted Shares Outstanding | 0.59% | 53.69% | 609.62% | 620.44% | 624.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |